Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy

OBJECTIVE: To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMN(Rx)), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA). METHODS: Nusinersen was...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiriboga, Claudia A., Swoboda, Kathryn J., Darras, Basil T., Iannaccone, Susan T., Montes, Jacqueline, De Vivo, Darryl C., Norris, Daniel A., Bennett, C. Frank, Bishop, Kathie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782111/
https://www.ncbi.nlm.nih.gov/pubmed/26865511
http://dx.doi.org/10.1212/WNL.0000000000002445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782111/
https://www.ncbi.nlm.nih.gov/pubmed/26865511
http://dx.doi.org/10.1212/WNL.0000000000002445

Ejemplares similares